Immunocore, the world's leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announced an investment from the Bill & Melinda Gates Foundation to support the development of Immunocore's soluble TCR-based therapeutics for infectious diseases.
The Bill & Melinda Gates Foundation will invest up to $40 million in Immunocore to support development of Immunocore's ImmTAV (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB (Immune mobilising monoclonal TCRs Against Bacteria) therapeutics for infectious diseases that pose a global health challenge.
The collaboration will discover and develop ImmTAV and ImmTAB molecules for the treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) where the TCR-based therapeutics have the potential to reduce treatment timelines and improve patient outcomes. Immunocore will also continue expanding its platform technology to enable therapeutics with broad coverage of the affected disease population.
The investment by the Bill & Melinda Gates Foundation was made as part of its programme-related investments (PRI) strategy, which aims to stimulate private sector-driven innovation, encourage market-driven efficiencies and attract external capital to priority global health and development initiatives that improve the lives of the world's most vulnerable people.
Buckinghamshire tech company Halma has acquired transport safety firm MK Test Systems Limited. Headquartered in…
BRiCS Development has secured an £11.55 million finance facility with Paragon Bank’s Development Finance team…
IT services and solutions company Mintivo has appointed Alex Jukes as its new Managing Director…
Bartlett Tree Experts have announced its intention to build a new arboretum and research facility…
The creation of a first-of-its-kind imaging system at the University of Surrey could help the…
Open Sight, which provides support across Hampshire to those living with or at risk of…